Skip to content

    Cancer Health Center

    Font Size

    Oropharyngeal Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage IV Oropharyngeal Cancer


    Concomitant Chemoradiation Therapy

    Concomitant chemoradiation therapy is a standard treatment option for locally advanced (stage III and stage IV) oropharyngeal carcinoma. A meta-analysis of 93 randomized, prospective head and neck cancer trials published between 1965 and 2000 showed a 4.5% absolute survival advantage in the subset of patients receiving chemotherapy and radiation therapy.[5][Level of evidence: 2A] Patients receiving concomitant chemotherapy had a greater survival benefit than those receiving induction chemotherapy.

    Concomitant Radiation Therapy With Targeted Agents

    In a randomized trial of locally advanced head and neck cancer patients, curative-intent radiation therapy alone (213 patients) was compared with radiation therapy plus weekly cetuximab (211 patients).[6] The initial dose was 400 mg/m2 of body-surface area a week before starting radiation therapy followed by a weekly dose of 250 mg/m2 of body-surface area for the duration of radiation therapy. At a median follow-up of 54 months, patients treated with cetuximab and radiation therapy demonstrated significantly higher progression-free survival (hazard ratio [HR] for disease progression or death, 0.70; P = .006). Patients in the cetuximab arm experienced higher rates of acneiform rash and infusion reactions, although the incidence of other grade 3 or higher toxicities, including mucositis, did not differ significantly between the two groups. This study allowed altered-fractionation regimens to be used in both arms.[6,7][Level of evidence: 1iiA]

    Induction Chemoradiation Therapy Followed by Concomitant Chemoradiation Therapy

    Two published, randomized trials that compared concomitant chemoradiation therapy with induction chemotherapy followed by concomitant chemoradiation therapy for locally advanced oropharyngeal cancer failed to show a survival advantage for induction chemotherapy regimens.[8,14] However, these studies did not stratify for human papillomavirus status, and the role of induction chemotherapy remains unclear.

    Altered Fractionation

    Radiation therapy alone with altered fractionation may be used for patients with locally advanced oropharyngeal cancer who are not candidates for chemotherapy. Altered fractionation radiation therapy yields a higher locoregional control rate than SFX for patients with stage III and stage IV oropharyngeal cancer. The long-term analysis of randomized trial RTOG-9003 included the following four radiation therapy treatment arms:

    1. Standard fractionation (SFX) to 70 Gy in 35 daily fractions for 7 weeks.
    2. Hyperfractionation (HFX) to 81.6 Gy in 68 twice-daily fractions for 7 weeks.
    3. Accelerated fractionation to 67.2 Gy in 42 fractions for 6 weeks with a 2-week rest after 38.4 Gy.
    4. Accelerated continuous fractionation (AFX-C) to 72 Gy in 42 fractions for 6 weeks.
    1 | 2 | 3
    Next Article:

    Today on WebMD

    man holding lung xray
    What you need to know.
    stem cells
    How they work for blood cancers.
    woman wearing pink ribbon
    Separate fact from fiction.
    Colorectal cancer cells
    Symptoms, screening tests, and more.
    Jennifer Goodman Linn self-portrait
    what is your cancer risk
    colorectal cancer treatment advances
    breast cancer overview slideshow
    prostate cancer overview
    lung cancer overview slideshow
    ovarian cancer overview slideshow
    Actor Michael Douglas